arrow
E

Erin S. Harvey

University of Newcastle
H指数:12
被引数:1,108

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Real-World Controlled Multicentre Study Evaluating the Association Between Benralizumab Therapy and Major Outcomes in Severe Asthma

一项真实世界多中心对照研究,评估苯瑞利珠单抗治疗与重度哮喘主要结局的关联

2026-05-270
OAAI
Mepolizumab treatment and reduced oral corticosteroid exposure improves symptoms of depression and anxiety in severe eosinophilic asthma: data from the Australian Mepolizumab Registry

Mepolizumab治疗和减少口服糖皮质激素暴露可改善重症嗜酸性哮喘患者的抑郁和焦虑症状:来自澳大利亚Mepolizumab登记研究的数据

2025-09-010
PRE
Effect of add-on therapies (mepolizumab, omalizumab or azithromycin) on asthma remission in severe asthma
2023-10-270
PRE
Impact of Landscape Fire Smoke Exposure on Patients With Asthma With or Without Laryngeal Hypersensitivity

景观火灾烟雾暴露对有或没有喉部超敏反应的哮喘患者的影响

2023-10-015
PRE
Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients

生物制剂 (美泊利单抗和奥马珠单抗) 诱导重症哮喘患者的缓解

2023-08-2514
OA
Comorbidities Modify the Phenotype but Not the Treatment Effectiveness to Mepolizumab in Severe Eosinophilic Asthma

合并症会改变表型,但不会改变美泊利单抗在严重嗜酸性粒细胞性哮喘中的治疗效果

2023-03-019
PRE
Mepolizumab and Oral Corticosteroid Stewardship: Data from the Australian Mepolizumab Registry

美泊利单抗和口服皮质类固醇管理: 来自澳大利亚美泊利单抗注册中心的数据

2021-07-0115
PREAI
Characterization of Severe Asthma Worldwide Data From the International Severe Asthma Registry
CHEST
IF8.6
2020-04-01205
OAAI
Mepolizumab effectiveness and identification of super-responders in severe asthma
2020-03-05132
OAAI
Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study
2019-02-0145
OAAI
Identification of treatable traits in a severe asthma registry: prevalence and exacerbation predictors
2018-11-190
PRE
Treatable traits can be identified in a severe asthma registry and predict future exacerbations
2018-09-19146
OAAI
Working while unwell: Workplace impairment in people with severe asthma
2018-05-1762
OAAI